Growth Hormone Secretagogues: Do They Beat Direct HGH?
Secretagogues raise GH pulses 70-100% but leave serum GH far below injected levels — with thin outcome data.
Growth hormone secretagogues (GHS) — peptides marketed to prompt your own body to release more growth hormone — are often pitched as a smarter, safer alternative to injecting growth hormone directly. The pitch contains a real physiological idea, and a set of trade-offs the marketing tends to skip. Whether they “beat” direct HGH depends on what you are actually trying to do.
Two different approaches
Direct recombinant human growth hormone (rhGH) supplies the hormone itself, bypassing the pituitary and often producing persistent, supra-physiological serum GH. Secretagogues — a category that includes GH-releasing hormone analogs and ghrelin-mimicking compounds like ibutamoren (MK-0677) and capromorelin — instead stimulate the pituitary to release its own GH, and feedback through IGF-1 limits overstimulation.
The difference in scale matters. In a 2023 review in The Journals of Gerontology: Series A, Smith and Thorner note that chronic GHS dosing increases the amplitude of GH pulses by roughly 70–100% — restoring secretion in older adults toward levels seen in 20- to 30-year-olds — yet serum GH stays substantially lower than what injected rhGH produces.
Secretagogues raise your own pulsatile GH, but to levels far below those of rhGH injections. That preserves feedback control — a real conceptual advantage — but it is not the same as a proven clinical one.
What the body-composition data actually shows
In trials of ibutamoren and capromorelin reviewed by Smith and Thorner, roughly a year of dosing produced consistent body-composition changes: increased fat-free mass, fat redistributed toward the limbs, higher total body weight, and mild, non-clinically-significant insulin resistance.
The catch is that these shifts did not reliably translate into outcomes people care about. The functional gains were modest and concentrated in sarcopenic or functionally declining populations. In healthy older adults, ibutamoren produced no significant improvement in muscle strength, quality of life, or cognition.
The trade-offs the pitch skips
- Outcome data is thin. The same review flags that few studies measure clinically significant endpoints like exercise tolerance and quality of life, limiting any judgment of real-world utility.
- Not effect-free. Even mild insulin resistance is a real downstream signal; “indirect” does not mean “consequence-free.”
- Quality and regulation. Many marketed peptides move through poorly regulated channels with variable purity.
So, do they beat direct HGH?
For diagnosed GH deficiency, established rhGH therapy is the studied path, not gray-market secretagogues. For the optimization claims that dominate marketing — leaner body, faster recovery, slower aging in healthy people — the controlled evidence for either approach is weak.
The takeaway
Secretagogues have a genuinely elegant mechanism: they boost your own GH pulses 70–100% while keeping serum GH and feedback closer to physiological. But the body-composition changes they produce have not reliably become meaningful functional benefits in healthy adults, and the outcome data remains thin. Treat the optimization claims with skepticism and leave true GH deficiency to medical care.